Hybio Pharmaceutical Co., Ltd. is engaged in the extensive research, development, production, and distribution of a diverse portfolio of therapeutic peptides and oligonucleotide drugs across global markets. The company's innovative product lines include advanced peptide formulations and active pharmaceutical ingredients addressing significant health challenges such as diabetes and metabolic disorders with offerings like liraglutide, semaglutide, and exenatide. They also provide treatments for conditions impacting the digestive and endocrine systems, including terlipressin, desmopressin, and linaclotide, alongside solutions for obstetrics and gynecology like ganirelix, cetrorelix, and atosiban. Furthermore, Hybio extends its expertise through comprehensive contract research organization (CRO) and contract development and manufacturing organization (CDMO) services, encompassing peptide API synthesis, formulation development, and regulatory support that meets stringent global GMP standards, including those of the EU and FDA. The company, established in 1998, is headquartered in Shenzhen, China, and continues to expand its reach and capabilities, notably securing significant funding and forging new partnerships in 2025 to advance its weight-loss drug pipeline and international collaborations.